Searching for an endogenous anti-alzheimer molecule: Identifying small molecules in the brain that slow alzheimer disease progression by inhibition of β-amyloid aggregation

Journal of Psychiatry and Neuroscience

Volumn 38, Issue 4, 2013, Pages 269-275

  Meek, Autumn R ^a   Simms, Gordon A ^a   Weaver, Donald F ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYANTHRANILIC ACID; AMYLOID BETA PROTEIN; PHOSPHOSERINE; THIOFLAVINE;

ALZHEIMER DISEASE; ARTICLE; COMPUTER MODEL; CORRELATION ANALYSIS; DISEASE COURSE; IN VITRO STUDY; NEUROTOXICITY; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84879647394     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.120166     Document Type: Article

References (30)

1. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86.
2. Hanyu H, Sato T, Hirao K, et al. The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer's disease: a longitudinal SPECT study. J Neurol Sci 2010;290:96-101.
3. Lahiri DK, Greig NH. Lethal weapon: amyloid β-peptide, role in the oxidative stress and neurodegeneration of Alzheimer's disease. Neurobiol Aging 2004;25:581-7.
4. Walsh DM, Selkoe DJ. A. β Oligomers - a decade of discovery. J Neurochem 2007;101:1172-84.
5. Giulian D, Haverkamp LJ, Yu J, et al. The HHQK domain of β-amyloid provides a structural basis for the immunopathology of Alzheimer's disease. J Biol Chem 1998;273:29719-26.
6. Yoda M, Miura T, Takeuchi H. Non-electrostatic binding and selfassociation of amyloid β-peptide on the surface of tightly packed phosphatidylcholine membranes. Biochem Biophys Res Commun 2008;376:56-9.
7. Fändrich M, Schmidt M, Grigorieff N. Recent progress in understanding Alzheimer's β-amyloid structures. Trends Biochem Sci 2011;36:338-45.
8. Morita M, Vestergaard M, Hamada T, et al. Real-time observation of model membrane dynamics induced by Alzheimer's amyloid beta. Biophys Chem 2010;147:81-6.
9. Lambert J-C, Amouyel P. Genetic heterogeneity of Alzheimer's disease: complexity and advances. Psychoneuroendocrinology 2007; 32:S62-70.
10. Martins RN, Hallmayer J. Age at onset: important marker of genetic heterogeneity in Alzheimer's disease. Pharmacogenomics J 2004;4:138-40.
11. Thalhauser CJ, Komarova NL. Alzheimer's disease: rapid and slow progression. J R Soc Interface 2012;9:119-26.
12. Cummings JL. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiol Aging 2000;21:845-61.
13. Stephenson VC, Heyding RA, Weaver DF. The "promiscuous drug concept" with applications to Alzheimer's disease. FEBS Lett 2005; 579:1338-42.
14. Mayo SL, Olafson BD, Goaddard WA III. DREIDING: a generic force field. J Phys Chem 1990;94:8897-909.
15. 2. Version 4.10. San Diego (CA): Accelrys Inc.; 2005.
16. Talafous J, Marcinowski KJ, Klopman G, et al. Solution structure of residues 1-28 of the amyloid beta-peptide. Biochemistry 1994;33:7788-96.
17. Sticht H, Bayer P, Willbold D, et al. Structure of amyloid A4-(1-40) peptide of Alzheimer's disease. Eur J Biochem 1995;233:293-8.
18. Coles M, Bicknell W, Watson AA, et al. Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it? Biochemistry 1998; 37:11064-77.
19. Crescenzi O, Tomaselli S, Guerrini R, et al. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem 2002;269: 5642-8.
20. Zirah S, Kozin SA, Mazur AK, et al. Structural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging. J Biol Chem 2006;281:2151-61.
21. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res 2000;28:235-42.
22. Brooks BR, Bruccoleri RE, Olafson BD, et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983;4:187-217.
23. QUANTA2005. Version 05.0417. San Diego (CA): Accelrys Software Inc.; 2006.
24. Molecular Operating Environment. Version 2010.10. Montréal (QC): Chemical Computing Group Inc.; 2010.
25. Tomaselli S, Esposito V, Vangone P, et al. The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. ChemBioChem 2006;7:257-67.
26. Cohen T, Frydman-Marom A, Rechter M, et al. Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 2006;45:4727-35.
27. Rauw GA, Grant SL, Labrie V, et al. Determination of L-serine-Ophosphate in rat and mouse brain tissue using high-performance liquid chromatography and fluorimetric detection. Anal Biochem 2010;405:260-2.
28. Heese K, Nagai Y, Sawada T. Induction of rat L-phosphoserine phosphatase by amyloid-β (1-42) is inhibited by interleukin-11. Neurosci Lett 2000;288:37-40.
29. Klunk WE, McClure RJ, Pettegrew JW. L-phosphoserine, a metabolite elevated in Alzheimer's disease, interacts with specific L-glutamate receptor subtypes. J Neurochem 1991;56:1997-2003.
30. Bonda DJ, Mailankot M, Stone JG, et al. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep 2010;15:161-8.